Effect of concurrent zidovudine use on the resistance pathway selected by abacavir‐containing regimens
Effect of concurrent zidovudine use on the resistance pathway selected by abacavir‐containing regimens
复制标题
同时使用齐多夫定对含阿巴卡韦方案选择的耐药途径的影响
作者：
E. R. Lanier;N. Givens;C. Stone;P. Griffin;D. Gibb;S. Walker;M. Tisdale;D. Irlbeck;M. Underwood;M. H. S. Clair;M. Ait‐Khaled
Abacavir (ABC) selects for four mutations (K65R, L74V, Y115F and M184V) in HIV‐1 reverse transcriptase (RT), both in vitro and during monotherapy in vivo. The aim of this analysis was to compare the selection of these and other nucleoside reverse transcriptase inhibitor (NRTI)‐associated mutations by ABC‐containing therapies in the presence and absence of concurrent lamivudine (3TC) and/or zidovudine (ZDV) and to assess the effect of these mutations on phenotypic susceptibility to the NRTIs.
